ACTRN12617001247369暂停2 期
Randomised, placebo-controlled, double-blind, cross-over, multi-centre study to evaluate the efficacy and safety of a Chinese herbal medicine (Shu Gan Liang Xue Decoction) to alleviate vasomotor symptoms in breast cancer survivors
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •1)Female, over 18 years, diagnosed with Stage 1-3 breast cancer, 2) completed surgery, chemotherapy and/or radiation. 3) If prescribed an estrogen-blocking medication i.e. tamoxifen or aromatase inhibitor stable for > 2 months prior to the study and unlikely to be changing estrogen-blocking medication during the study. 4) Protocol defined adequate hepatic and renal function. 5) Written informed consent.
排除标准
- •Excluded if they have 1) poorly controlled hypertension, hypothyroidism or diabetes mellitus 2) hyperthyroidism 3) use of Hormone Replacement Therapy (HRT) - washout period 8 weeks 4)Unwilling to refrain from other remedies for hot flushes during study 5) pregnant or breast-feeding 9) use on blood-thinning medication 10) any other chronic condition deemed inappropriate by the clinician for the trial 11) Lack of, or withdrawal of informed consent. 12) Participation in another trial.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial with herbal Bronchipret and Sinupret to evaluate the acceleration of mucociliary clearance ( the self-clearing mechanism of the bronchi)EUCTR2012-004864-24-BEBionorica SE
进行中（未招募）
不适用
Clinical study with randomly into groups divided patients (investigational or ineffective control medication), where neither the doctor nor the patient's know the assignment, to determine the effect of the investigational product (Empagliflozin) on the circulation in the smallest vessels of the body.Type 2 diabetes mellitusMedDRA version: 17.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 100000004861EUCTR2014-003053-34-DEIPPMed – Institut für Pharmakologie und Präventive Medizin GmbH
已完成
不适用
Influence of Silexan on pharmacokinetics and hormonal activity in females taking oral contraceptivesPharmacokinetics of ethinyl estradiol and levonorgestrelISRCTN52706881Dr. Willmar Schwabe GmbH & Co. KG (Germany)24
尚未招募
不适用
ESMAVAC - 1MalariaPACTR201712002879427Centre de Recherches Médicale de Lambaréné
进行中（未招募）
不适用
CONCERTA Lab School StudyMedDRA version: 18.0Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderSystem Organ Class: 100000004873Attention Deficit Hyperactivity DisorderEUCTR2015-001042-28-Outside-EU/EEAOrtho-McNeil Janssen Scientific Affairs LLC89